Uncoupling conformational states from activity in an allosteric enzyme by Pisco, João P et al.
 
 
University of Birmingham
Uncoupling conformational states from activity in
an allosteric enzyme
Pisco, João P; de Chiara, Cesira; Pacholarz, Kamila J; Garza-Garcia, Acely; Ogrodowicz,
Roksana W; Walker, Philip A; Barran, Perdita E; Smerdon, Stephen J; de Carvalho, Luiz
Pedro S
DOI:
10.1038/s41467-017-00224-0
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Pisco, JP, de Chiara, C, Pacholarz, KJ, Garza-Garcia, A, Ogrodowicz, RW, Walker, PA, Barran, PE, Smerdon,
SJ & de Carvalho, LPS 2017, 'Uncoupling conformational states from activity in an allosteric enzyme', Nature
Communications, vol. 8, no. 1, 203. https://doi.org/10.1038/s41467-017-00224-0
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 04/11/2019
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
ARTICLE
Uncoupling conformational states from activity in
an allosteric enzyme
João P. Pisco 1, Cesira de Chiara1, Kamila J. Pacholarz2, Acely Garza-Garcia 1, Roksana W. Ogrodowicz3,
Philip A. Walker3, Perdita E. Barran 2, Stephen J. Smerdon4 & Luiz Pedro S. de Carvalho 1
ATP-phosphoribosyltransferase (ATP-PRT) is a hexameric enzyme in conformational
equilibrium between an open and seemingly active state and a closed and presumably
inhibited form. The structure-function relationship of allosteric regulation in this system is
still not fully understood. Here, we develop a screening strategy for modulators of ATP-PRT
and identify 3-(2-thienyl)-L-alanine (TIH) as an allosteric activator of this enzyme. Kinetic
analysis reveals co-occupancy of the allosteric sites by TIH and L-histidine. Crystallographic
and native ion-mobility mass spectrometry data show that the TIH-bound activated form of
the enzyme closely resembles the inhibited L-histidine-bound closed conformation, revealing
the uncoupling between ATP-PRT open and closed conformations and its functional state.
These ﬁndings suggest that dynamic processes are responsible for ATP-PRT allosteric
regulation and that similar mechanisms might also be found in other enzymes bearing a
ferredoxin-like allosteric domain.
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A llostery is the change in protein activity triggered bybinding of a ligand (effector) at a site different from theactive site1, 2. Feedback allosteric circuits are a direct, rapid
and efﬁcient mechanism of metabolic control. These feedback
allosteric circuits contribute to metabolic homeostasis by translating
changes in the concentration of metabolites to enzyme activity and
ultimately cellular responses3. Protein domains with a ferredoxin-
like (FL) βαββαβ topology have been widely co-opted throughout
evolution for allosteric control. Particular FL domains have evolved
to recognize and respond to one -or sometimes more- molecules of
very distinct nature, including nucleotides4, heavy metals5, and
various amino acids. Aspartate carbamoyltransferase (an FL domain
containing enzyme) is one of such enzymes, where multiple
nucleotides inhibit or activate catalysis. Elegant work describing the
complex analysis of regulation by multiple effectors (physiologic
ligands) has been carried out6.
Feedback regulation via amino acid binding to FL domains
is widespread in enzymes involved in amino acid biosynthetic
pathways (Supplementary Fig. 1). Examples in the biosynthesis
of aromatic amino acids include eukaryotic phenylalanine-
4-hydroxylase (PAH; 1.14.16.1), regulated type Iβ 3-deoxy-
D-arabino-heptulosonate 7-phosphate synthase (DAH7PS;
2.5.1.54)7 and the bacterial and plant chorismate mutase/
prephenate dehydratase (PDT; 5.4.99.5/4.2.1.51)8. In branched
amino acids biosynthesis, proteins regulated via FL domains
are the bacterial and plant biosynthetic threonine ammonia-lyase
(EC 4.2.1.19)9 and the bacterial acetohydroxyacid synthase
isozyme III (AHAS; EC 2.2.1.6)10. Other examples are in
Thr, Lys, Met and Ile biosynthesis, the bifunctional chloroplastic
aspartokinase/homoserine dehydrogenase 2 (AKHSDH2; 2.7.2.4/
1.1.1.3), and in Ser biosynthesis, D-3-phosphoglycerate
dehydrogenase types I and II (PHGDH; 1.1.1.95). The long
form of ATP-phosphoribosyltransferase (ATP-PRT; EC 2.4.2.17),
the enzyme that catalyses the ﬁrst committed step of L-histidine
(L-His) biosynthesis, is also feedback inhibited by L-His11, 12
(Supplementary Figs. 2 and 3) via a FL domain. Many of these
FL-regulated enzymes present in pathogenic bacteria, such as the
ATP-PRT from Mycobacterium tuberculosis, are essential
and have been proposed as attractive targets for antibacterial
drug discovery.
Protein domain structure databases place the FL domain of
ATP-PRT in the same superfamily as the cyclic-di-AMP receptor
family, peptidase S54, and the GlnB proteins13, 14. The deﬁning
attribute of the GlnB superfamily is that the FL domains arrange
in trimers with the β-sheet of each monomer positioned
orthogonally to one another14. Because of the common FL fold
and functional similarity, the regulatory domain of ATP-PRT has
also been associated with the aspartate kinase, chorismate mutase
and TyrA (ACT) superfamily15. The FL domains of GlnB and
ACT have no known evolutionary relationships and represent a
superfold that has likely emerged by convergence16.
Our understanding of the mechanisms of amino acid-binding
FL domain-mediated allosteric inhibition comes mostly from the
few available crystal structures of free vs. inhibited forms. For
T. maritima DAH7PS and PHGDH, the available structures show
that effector binding triggers domain reorganization leading to
occlusion of the active site17, 18. In the case of ATP-PRT, an early
study proposed that L-His binding caused a transition from dimer
to hexamer19. However, more recent data show that both free and
inhibited ATP-PRT are hexameric but that the L-His-bound form
is more compact due to a slight rotation of the regulatory
domains12, 15, 20. We now understand crystal structures as being
the static snapshots of a continuum of conformations sampled
by the enzyme. In this light, ATP-PRT can be described to exist
in an equilibrium between a relaxed (R) hexamer and a tense (T)
compact hexamer, with L-His binding preferentially to the R state
and causing the population to shift to the T state21, 22.
In an effort to better understand the allosteric regulation
mechanism of ATP-PRT, we implemented a Compound
Screening in the Presence of an Inhibitor (CoSPI) strategy
(Fig. 1). CoSPI makes use of a known inhibitor to provide a
targeted and detailed discovery of compounds that have an effect
on activity of the enzyme as well as in its regulation. In contrast to
most screens employed to date, CoSPI identiﬁes molecules that
are only active in the presence of a regulator-enzyme complex.
This strategy led us to the discovery of 3-(2-Thienyl-L-alanine)
(TIH) as a non-essential activator of M. tuberculosis ATP-PRT.
Detailed kinetic measurements and structural characterization of
ATP-PRT in the presence of TIH and/or L-His allowed us to
probe the mechanism of allosteric regulation in ATP-PRT with
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Fig. 1 Schematic representation of CoSPI method vs conventional screenings. In the Compound Screening in the Presence of an Inhibitor (CoSPI) strategy,
complete IC50 curves are recorded for a known inhibitor in the presence of each of the test compounds. The enzyme is in blue, substrates in yellow, known
inhibitor in red and compound to test in green. The top panels show the single points observed in a conventional screening (red dots are missed hits, blue is
an activator and pink an inhibitor). The bottom panels show the information-rich patterns observed using CoSPI. Curves depict simulated data for an
inhibitor with IC50= 20 µM, Hill number of 1 and capable of full inhibition (100 to 0% activity). The red curve are the data for the known inhibitor in the
absence of other molecules. a Effects in the potency of the inhibitor. Green, increase in the apparent afﬁnity of the inhibitor. Orange, decrease in the
apparent afﬁnity of the inhibitor. b Effects in the activity of the enzyme independently of the inhibitor. Blue, increase in the activity of the enzyme.
Pink, decrease in the activity of the enzyme. c Effects in inhibitor-enzyme cooperativity. Cyan, increase in the cooperativity of inhibition. Grey, decrease
in the cooperativity of inhibition
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unexpected results. Activation and inhibition of ATP-PRT leads
to the same overall conformational tightening of the hexamer.
This decoupling of activity and conformation indicates that
allosteric regulation of ATP-PRT, and perhaps other FL domain
containing allosteric enzymes, is more complex than the simple
open–closed active–inactive model.
Results
CoSPI identiﬁes TIH as an activator of ATP-PRT. We carried
out a small, targeted version of CoSPI, to demonstrate its
ability to uncover non-canonical regulators of enzyme function.
By following the formation of phosphoribosyl-ATP (PR-ATP,
ε290= 3600M−1 cm−1), we tested the effect of 11 commercially
available L-His analogues, at a single concentration (1 mM), on
the inhibition of ATP-PRT by L-His (Fig. 2a and Supplementary
Fig. 4). Using as reference the activity values of uninhibited
enzyme and the IC50 of L-His in the absence of any additional
compounds (dashed lines in Fig. 2a), the selection of the best
candidates was straightforward. Analogues 2 and 6 showed a
change in L-His IC50 and uninhibited maximal activity. TIH,
compound 2, was chosen for further characterization as it had the
greatest effect. Addition of TIH to the reaction mixture resulted
in a linear increase in the L-His IC50, and a hyperbolic (saturable)
increase in the reaction velocity (Fig. 2b, c). We conﬁrmed the
activation of ATP-PRT by TIH by determining the concentration
required to half-maximal activation (AC50) (Fig. 2d). TIH
increases ATP-PRT activity up to 433± 18 %, with an AC50 of
1.5± 0.2 mM.
TIH increases ATP-PRT turnover rate. According to the Botts
and Morales general modiﬁer mechanism (Fig. 2e)23, 24, the
presence of a modiﬁer (either an inhibitor or an activator) might
have an effect on the dissociation constant of the ternary enzyme-
substrate-modiﬁer complex, this effect is given by the constant α.
In addition, the modiﬁer can have an effect on kcat, which
is described by the coefﬁcient β. Non-essential activation is
generally characterized by a ligand that can bind and activate
an enzyme, not being essential for enzymatic activity. Values of
α lower than 1 and values of β higher than 1 are usually observed.
However, mixed-type systems where α and β are higher than 1 are
also possible, as are systems where α and β are both lower
than 125. We performed measurements of ATP-PRT activation by
TIH at different concentrations of either of the substrates, ATP or
PRPP. Coefﬁcients α and β were consistent with non-essential
activation in both cases (Fig. 2f, Supplementary Figs. 5 and 6).
For ATP we obtained a KA,ATP value of 1.5± 0.2 mM, an αATP
of 1.4± 0.2 and a βATP value of 4.9± 0.2. The activity of
the unactivated reaction was 0.17± 0.01 s−1 and the Km,ATP
0.10± 0.01 mM, in close agreement with values previously
reported12. In the case of varying concentrations of PRPP,
KA,PRPP was 2.1± 0.6 mM, α was 1.1± 0.4 and a β 4.9± 0.5. The
activity of the unactivated reaction was 0.21± 0.01 s−1 and the
Km,PRPP 0.19± 0.03 mM. These results indicate that TIH has little
effect on the stability of the tertiary complex, but is able to
increase the catalytic rate by up to 490%.
L-His and TIH binding are mutually affected. We performed
single inhibition measurements with co-variation of either sub-
strate, ATP or PRPP, and L-His. Results showed linear uncom-
petitive inhibition by L-His vs. ATP, with a Ki,ATP of 20± 1.0 µM,
and linear noncompetitive inhibition vs. PRPP, with a Ki,PRPP of
16± 1.0 µM as previously reported12. Following the method
described by Andi and collaborators26, we repeated the inhibition
experiment at four different concentrations of TIH (0, 0.25, 0.8
and 4 mM) (Fig. 3a). Increasing the concentration of TIH resulted
in higher values of Vmax and, therefore kcat, and Ki,ATP for L-His
inhibition (Table 1). As expected, the afﬁnity of ATP was not
considerably affected. A secondary replot of the data in Fig. 3a
revealed a linear dependence of both the slopes and the intercepts
as a function of L-His concentration (Fig. 3b). Tertiary replots of
the slopes and intercepts of the data in Fig. 3b showed an
exponential dependence on activator concentration (Fig. 3c).
Three different KA values could be determined from the tertiary
replots using eq. 7 (Methods; Table 2). Each of the KA values
corresponds to the afﬁnity of TIH to one of the following
complexes, ESP (intercept of the slope, KA1,ATP), ESPSA (intercept
of the intercept, KA3,ATP) and ESPSAI (slope of the intercept,
KA4,ATP), where I is the inhibitor, SA is ATP and SP is PRPP, as
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Fig. 2 CoSPI discovery of a non-essential activator of ATP-PRT. a L-His IC50 and %Activity data obtained in the presence of each of 11 L-His analogues using
CoSPI. The dashed lines mark L-His IC50 and the activity of uninhibited ATP-PRT. Error bars indicate the s.d. Number of replicates (n)= 3 b Representative
inhibition curves determined for L-His in the presence of 0 (black), 0.5 (purple), 1 (orange), 2 (yellow) and 4 (green) mM compound 2, TIH (shown in the
upper right corner). Circles are experimental measurements and lines the best ﬁt to Eq. 2 in Methods section. c Replot of the data in b, showing hyperbolic
increase in ATP-PRT activity (circles) and linear increase in L-His IC50 (squares), in the presence of TIH. The lines are the best ﬁt to Eq. 1 in Methods and a
linear regression of the data, respectively. Error bars indicate the s.e.m. d Steady-state kinetics of ATP-PRT activation by TIH. Circles are data points and the
line is the best ﬁt to Eq. 3 in Methods section, n= 2. e General modiﬁer mechanism depicting an activator, E, enzyme; S, substrate; A, activator; P, product.
f Double-reciprocal plot highlighting the non-essential activation pattern obtained when varying the concentration of TIH. Circles are data points obtained
with 0 (black), 0.25 (red), 0.8 (blue) and 4 (green) mM TIH and lines are the best ﬁt of the entire data set to Eq. 4 in Methods section. Error bars indicate the
s.d., n= 2
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illustrated in the model (Fig. 3d). The ratio of KA3,ATP/KA4,ATP
reports on the afﬁnity of the activator for the ESASP
complex, in the presence of the inhibitor, and is characterized by
α3/4,ATP= 2.60± 0.66; the value higher than 1 indicates that TIH
has higher afﬁnity for ATP-PRT in complex with L-His. Also
determined from the tertiary replots (Supplementary Fig. 8a and
Supplementary methods), the activation of ATP-PRT by TIH is
higher when TIH binds to ATP-PRT in the presence of L-His. An
18-fold activation by TIH was observed in the presence of both
substrates and L-His in contrast to a 6-fold activation in the
absence of inhibitor; when TIH binds to ATP-PRT in complex
with PRPP only a 11-fold activation is observed (Table 2 and
Fig. 3d). When varying PRPP concentration (Supplementary
Figs. 7 and 8b), four different KA’s could be determined. Once
again, the results show that TIH has higher afﬁnity for ATP-PRT
in complex with L-His with values of α1/2,PRPP= 1.92± 0.33 and
α3/4,PRPP= 3.27± 0.98, and fold-activation values were as high as
29, in the presence of L-His and ATP.
TIH rescues ATP-PRT activity in the presence of L-His. At a
saturating concentration of L-His (400 µM, 20-fold Ki), ATP-PRT
is fully inhibited, showing no activity (Fig. 4a). Recovery of the
activity can be achieved simply by addition of TIH to the
inhibited reaction mixture. At a concentration close to 4 mM TIH
(2-fold higher than KA ~ 2mM) 100% of the activity is restored
and further activation is achieved with higher concentrations of
TIH. Figure 4b shows a contour map that better illustrates the
entire activity landscape obtained for ATP-PRT, in the presence
of L-His and TIH, at all concentrations tested. Simultaneous
binding of TIH and L-His to the hexamer was conﬁrmed
through a competition saturation transfer difference (STD) NMR
experiment27. In an STD NMR experiment, signals are observed
only for ligand protons in contact with the protein. In the absence
of L-His signals of the TIH protons are observed (Fig. 4c, bottom
spectrum). Increasing concentrations of L-His result in the
progressive reduction of the TIH peaks and the appearance of
L-His proton signals, indicating displacement of TIH by L-His.
Both TIH and L-His-bound ATP-PRT are in the T conforma-
tion. We solved the crystal structures of ATP-PRT in complex
with TIH or L-His by molecular replacement using the
unliganded coordinates of the ATP-PRT ternary complex with
L-His and AMP (1NH8) as a search model. Crystals of the two
complexes grew in identical crystallization conditions and to
comparable resolution, thus being an ideal case for a direct and
detailed comparison between structures (Table 3). All ATP-PRT
crystals obtained in complex with either L-His or TIH invariably
belonged to the H 3 2 space group with one protein molecule in
the asymmetric unit. The hexamer representing the biological
assembly of ATP-PRT was obtained by symmetry operations
preventing us from solving the structure of an ATP-PRT complex
with both L-His and TIH.
As expected on the basis of the overall structural similarity
between the two ligands and the results of the competition
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Fig. 3 L-His inhibition kinetics in the presence of TIH. a Four double-reciprocal plots showing linear uncompetitive inhibition patterns determined for L-His in
the presence of 0 (black), 0.25 (red), 0.8 (blue) and 4 (green) mM TIH, at ﬁxed variable concentrations of ATP. Results are representative of two independent
experiments. Points are experimental data obtained with 0 (black circles), 12 (white circles), 24 (black squares) and 36 (white squares) µM L-His. Lines are the
best ﬁt of each uncompetitive pattern data set to Eq. 5 in Methods section. b Secondary replot of the slopes (circles) and intercepts (squares) of the data shown
in a. c Tertiary replots of the slopes (top panel) and intercepts (lower panel) of the data shown in b. Slope of the intercept (triangles), intercept of the intercept
(diamonds) and intercept of the slope (hexagons). Lines are the best ﬁt to Eq. 7 in Methods section. d Kinetic model for a combination of uncompetitive
inhibition and non-essential activation. The complexes in boxes are in equilibrium. The blue box indicates that this complex is always present in the assay.
E, Enzyme; SA, ATP; SP, PRPP; A, TIH; I, L-His; P, Product
Table 1 Steady-state kinetic parameters for ATP-PRT
inhibition in the presence of TIH
[TIH] (mM)
Parameters 0 0.25 0.8 4
Vmax (s−1) 0.21± 0.01 0.28± 0.01 0.38± 0.01 0.76± 0.01
Km,ATP (mM) 0.23± 0.03 0.20± 0.02 0.18± 0.02 0.16± 0.02
Ki,ATP (mM) 20± 1 25± 1 41± 2 89± 5
Table 2 Steady-state kinetic parameters for ATP-PRT
activation in the presence of L-His
Parameters Best ﬁt Fold activation
KA1,ATP (mM) 0.50± 0.01 10.9
KA2,ATP (mM) — —
KA3,ATP (mM) 0.75± 0.10 6.6
KA4,ATP (mM) 0.29± 0.06 18.1
α1/2,ATP — —
β1/2 ATP 2.60± 0.66 —
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kinetics experiments, TIH was found to bind in the same
allosteric site as L-His (Fig. 5a, d and g), a site deﬁned by opposite
and complementing surfaces of two adjacent regulatory FL-like
domains. The position of the ligand in each complex was inferred
by the presence of positive density in the unbiased difference map
derived by molecular replacement (Supplementary Fig. 9). Fitting
of the ligands and reﬁnement of the structure resulted in identical
ligand orientation (Fig. 5d and g). We conﬁrmed the identity of
TIH by calculating the anomalous scattering difference map for a
data set of the complex collected at 1.8 Å, which exhibited
positive density for the sulphur in the thiophenyl moiety and
allowed unambiguous assignment of the correct orientation of the
ring (Supplementary Fig. 10a). Side chains of the residues directly
interacting with the ligand assume identical conformations in the
two complexes with the only exception of D216 (Fig. 6a and b). In
the ATP-PRT/L-His complex D216 interacts with the L-His side
chain via a water molecule-mediated H-bond to ND1, but in the
complex with TIH the water molecule is missing and its position
occupied by one of two observed conformations for the
D216 side chain which is oriented towards the thiophenyl ring.
Taken together, the overall similarity between “inhibited” and
“activated” structures and the differential conformation of D216
in both complexes could indicate that D216 is a “trigger” for
inhibition of ATP-PRT. Steady-state kinetics studies on the
D216V mutant support the interpretation of a speciﬁc role for
D216 in L-His recognition and inhibition. D216V ATP-PRT is no
longer inhibited by L-His (up to 10 mM); however, it is still
activated by TIH, in the presence or absence of L-His, with similar
afﬁnity to the wild type (Fig. 6c and d). The other noticeable
structural difference in the allosteric binding site is the absence in
the TIH complex of the H-bond observed between HE2 of L-His
and the carbonyl oxygen of A273. The missing H-bonds are likely
to account for the three orders of magnitude difference in the
apparent afﬁnity of the two ligands and their opposite effect on
enzymatic activity (Fig. 6).
The comparison between the structures of both the monomer
and the crystallographic hexamer revealed that the L-His inhibited
and the TIH activated complexes are highly superimposable and
share the same tense (T) conformation so far attributed to the
inactive state of the enzyme (Supplementary Fig. 11)19, 20, 28.
Furthermore, no appreciable differences between the two
complexes were observed in the side-chain orientation of the
residues expected to be involved in substrate and/or product
binding by virtue of similarity with the E. coli ATP-PRT
in complex with PR-ATP (PDB code: 1Q1K)28 and C. jejuni
ATP-PRT in complex with ATP (PDB code: 4YB7)20 (Supple-
mentary Fig. 12). The mean global RMSD between the two
complexes calculated over the entire sequence (residues 1–284)
was 0.12 and 0.61 Å for the backbone and heavy atoms,
respectively. The RMSD value between the open unliganded
ATP-PRT (1NH7) and the structures in this work was of
4.24/4.56 Å (backbone/heavy atoms) and 4.24/4.55 Å for the
L-His- and TIH-complexes, respectively. The crystallographic
structures at 1.8 Å of the ATP-PRT/TIH complex obtained
from different crystallization conditions consistently showed
the hexamer in a T-state (Supplementary Fig. 10b).
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Table 3 Data collection and reﬁnement statistics
(molecular replacement)
ATP-PRT/
TIHa
ATP-PRT/TIH ATP-PRT/L-
His
Data collection
Space group H 3 2 (155) H 3 2 (155) H 3 2 (155)
Cell dimensions
a, b, c (Å) 115.48, 115.48,
124.60
117.51, 117.51,
127.36
117.01, 117.01,
127.33
α, β, γ (°) 90.00, 90.00,
120.00
90,00, 90.00,
120.00
90.00, 90.00,
120.00
Resolution (Å) 46.41–1.76 47.25–2.06 42.44–2.02
(1.79–1.76)b (2.12–2.06)b (2.07–2.02)b
Rsym or Rmerge 0.033 (0.828) 0.041 (0.690) 0.033 (0.714)
I/σI 20.6(1.0) 16.1(2.0) 22.3(2.1)
Completeness (%) 99.8 (98.2) 99.7 (99.9) 99.7 (100)
Redundancy 5.2 (3.6) 4.6 (4.8) 4.8 (5.1)
Reﬁnement
Resolution (Å) 47.25–2.06 42.44–2.02
(2.12–2.06) (2.07–2.02)
No. reﬂections 20989 22067
Rwork / Rfree 0.1975/0.2307 0.1979/0.2378
No. atoms 2274 2284
Protein 2166 2161
Ligand/ion 26 36
Water 82 87
B-factors
Protein 50.56 48.83
Ligand/ion 74.67 77.01
Water 52.47 52.90
R.m.s. deviations
Bond lengths (Å) 0.004 0.007
Bond angles (°) 0.64 0.86
aData set used for anomalous scattering difference map calculation
bNumber of crystals was one for each structure. Values in parentheses are for highest-resolution
shell
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Native mass spectrometry supports R to T conformation shift.
To complement our crystallographic results we employed native
ion-mobility mass spectrometry (IM-MS) to investigate the
equilibrium between the R- and T-states in the presence of either
L-His or TIH. We obtained data for unligated ATP-PRT and in
complex with L-His or TIH, at neutral pH (6.8) and in mildly
alkaline pH (9.0) conditions in which ATP-PRT is more active12
(Supplementary Table 1). Results at neutral pH (Fig. 5) showed
the existence of a pre-existing equilibrium between the R- (drift
time of 51.2 ms) and T- (drift time of 44.0 ms) states, with a
strong preference for the R-state. Addition of either L-His or TIH
shifted the equilibrium towards shorter drift times (44.1 and 44.2
ms, respectively), characteristic of the T-state. At basic pH,
unligated, L-His and TIH-bound ATP-PRT are all in the T-state
(Supplementary Fig. 13).
Discussion
Target-based small-molecule screenings are a valuable and widely
used approach for lead generation in drug discovery. In traditional
screenings compounds are tested against puriﬁed enzymes, with
the goal of detecting enzyme inhibition29, 30, activation31, or
binding to the target protein32, while other screenings test for
secondary ligands that only bind after the ﬁrst ligand binds33, 34.
Despite their undisputed usefulness, traditional screens fail to
detect compounds displaying less common or peculiar effects,
such as inﬂuencing the efﬁcacy or afﬁnity of a known effector, or
altering effector–enzyme cooperativity. In order to screen for these
effects, we developed CoSPI, a targeted screen of small molecules.
The screen is carried out in the presence of a known inhibitor, and
consists of determining and evaluating the entire inhibition proﬁle
(IC50 curve) of the known inhibitor in the presence of a single
ﬁxed concentration of each of the compounds. Hill number (nH),
Vmax and IC50 are then estimated from such curves and compared.
Three limiting behaviours can potentially be observed using a
CoSPI design (Fig. 1). First, compounds that have no effect on
their own but are able to increase or decrease the potency of the
known inhibitor (Fig. 1a). Second, compounds able to alter the
enzyme activity independently of the known inhibitor (Fig. 1b).
And third, compounds that do not alter enzyme activity but alter
the inhibitor-enzyme cooperativity (Fig. 1c). As proof of concept,
we used the CoSPI strategy to screen 11 L-His analogues for their
ability to modifyM. tuberculosis ATP-PRT activity in the presence
of its allosteric inhibitor L-His. The outcome of the screen was
simple and clear (Fig. 2a), and lead to the discovery of TIH, the
ﬁrst reported allosteric activator of ATP-PRT and in the whole
histidine biosynthesis pathway. Allosteric activators have only
recently emerged as valuable tools for the study of conformational
changes associated with enzyme activation, and of the biological
consequences of enzyme activation in the context of a speciﬁc
signalling/metabolic pathway35.
TIH is a non-essential ATP-PRT activator of weak molar
potency with KA,ATP value of 1.5± 0.2 mM and KA,PRPP value of
2.1± 0.6 mM. Nonetheless, it is able to activate ATP-PRT by up
40 6050
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Fig. 5 Crystal structure and native IM-MS of apo-, L-His-bound and TIH-bound ATP-PRT. Cartoon representation of the allosteric binding site in the
hexamer, surface representation viewed from the top and native drift time distribution of: a, b, c Apo- (PDB code 1NH7); d, e, f L-His-bound (PDB code
5LHU), and g, h, i TIH-bound (PDB code 5LHT) ATP-PRT. Allosteric domains are coloured in yellow while the catalytic domains are coloured in blue.
The bars represent the span of the different molecule complexes. Distances have been measured between coupled Cα atoms of I269 (yellow bars) and
I129 (blue bars). The black arrow on c indicates the fraction of unliganded ATP-PRT in the T-state
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to 500%. TIH activation originates solely from a V-type effect,
this is, it increases the catalytic rate (β-value of 4.9) but has no
effect on Km (α-value ~1); this is a different type of activation
from most cases reported to date36–39. To the best of our
knowledge, a ﬁvefold increase in kcat is one of the highest
increases reported for a small-molecule allosteric activator.
Having a similar structure and judging by its effect on L-His IC50
(Fig. 2b and c) it was expected that TIH and L-His bound at the
same site. The results of the inhibition studies with co-variation of
either of the substrates and L-His, at four different concentrations
of TIH (Fig. 3a and Supplementary Fig. 7a) further supported this
idea. In these experiments, increasing concentrations of TIH did
not signiﬁcantly affect the afﬁnity of the substrates, but Ki values
for L-His increased linearly, indicating a strong effect of TIH on
L-His potency (Table 1 and Supplementary Fig. 7b). Furthermore,
and despite its weak potency, TIH at a concentration of twice KA
(4 mM) was sufﬁcient to fully activate ATP-PRT in the presence
of L-His at a concentration ≈ twice Ki (36 μM). Under these
conditions Vmax reached values close to those obtained in the
presence of saturating concentration of TIH (absence of L-His),
Va,max, justifying the increase in fold-activation values from 6 to
18-fold. To conﬁrm this behaviour, ATP-PRT activity was tested
at increasing concentrations of TIH in the presence of L-His at a
concentration of 20 times Ki (Fig. 4a), which fully abolishes
activity. Again we saw that TIH at a concentration of 2 times KA
is sufﬁcient to rescue ATP-PRT to normal activity levels. This
apparently counterintuitive behaviour, indicative of a “kinetic
superiority” of a low afﬁnity ligand over a high afﬁnity ligand may
occur because there are six L-His binding sites in the ATP-PRT
hexamer12, 19. The nH for L-His inhibition is 1.512, suggesting that
occupation of four of the six binding sites is sufﬁcient for full
inhibition of the hexamer, leaving two sites available for TIH
to bind and activate ATP-PRT (Supplementary Fig. 14). In
agreement with this hypothesis, TIH afﬁnity is higher when L-His
is bound to ATP-PRT, as revealed by values of α3/4,ATP, α1/2,PRPP
and α3/4,PRPP of 1.9-, and 3.3- and 2.6-fold, respectively. This
preference of TIH for the ATP-PRT- L-His complex is substrate
independent. In addition, the fold-activation obtained in the
presence of L-His is considerably higher than the fold-activation
obtained in its absence (Table 2 and Supplementary Fig. 7e), this
is because the very low Vmax values observed in the presence of
L-His increase substantially upon addition of TIH, until reaching
Va,max, giving higher values of fold-activation. There have been a
few reports of activators of bacterial enzymes in the literature,
including activators of cylindrical proteases40, 41, proteasome-
related HslV peptidase42 and glycoside hydrolase39. Nonetheless,
TIH seems to be a distinct small-molecule activator of a bacterial
enzyme, binding in the same site as the natural allosteric
inhibitor.
The similarity between the crystallographic structures of the
ATP-PRT hexamer in complex with the L-His or with TIH was
surprising. Despite exerting an opposite effect on the enzymatic
activity, both induce a rigid body conformational change that
re-orients the regulatory domain with respect to the catalytic
region leading to the compaction of the hexamer characteristic
of the T-state. To rule out the possibility that this was a
crystallization artefact, we performed measurements in the
“vapour phase” using native IM-MS, with equivalent results.
Our data suggest that there is not direct correlation between
R- and T-states and active and inactive conformations in ATP-
PRT. Instead, it is likely that other conformational states, less
populated than R- and T-, are critical for activity and/or that
there is an important dynamic contribution to the allosteric
mechanism.
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Fig. 6 Differential conformations and kinetics of wild-type and D216 ATP-PRT in the presence of L-His or TIH. Cartoon representation highlighting the
H-bonds surrounding L-His a and TIH b in their respective crystal structures. The D216 side chain in the TIH-bound ATP-PRT structure could be ﬁtted in
two conformations with 0.35 and 0.65 occupancy. Steady-state kinetics of ATP-PRT inhibition by L-His c, and activation by TIH d. WT (black circles), D216
V (red circles) and D216 V + 2mM L-His (blue circles), error bars indicate the s.d., n= 3. Circles are experimental measurements and lines are the best ﬁt to
Eq. 2 (Methods section) for inhibition by L-His and Eq. 4 (Methods section) for activation by TIH. Data for D216 V inhibition by L-His were ﬁt to a linear
regression. For WT, an IC50 for L-His of 22± 4 μM and an AC50 for TIH of 1.5± 0.2 mM were obtained. For D216 V, an AC50 for TIH of 1.7± 0.1 mM was
obtained, which did not change in the presence of 2 mM L-His, with an AC50 of 1.5± 0.1 mM. L-His (up to 10 mM) did not change D216 V activity and
therefore an IC50 could not be determined
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Given that substrate binding and product release can only take
place in the R state, the R- and T-states might reﬂect the
functional catalytic ‘cycle’ of ATP-PRT. We hypothesize that
activators and inhibitors have opposite effects on the rate of
sampling of the conformational ensemble. Thus, an activator may
increase turnover by accelerating the sampling rate, while an
inhibitor might slow it down. This hypothesis is consistent with
the fact that TIH activation is solely due to an increase in Vmax.
A detailed characterization of the conformational equilibrium
exchange rates in the presence and absence of effectors will
be required to test this hypothesis and is currently in progress.
Of particular interest is the possibility that the uncoupling
between R- and T-states and activity observed for ATP-PRT
might be a feature of other ferredoxin-like domain-containing
allosteric enzymes.
Methods
Materials. Buffers and L-His were purchased from Fisher Scientiﬁc. Except if
speciﬁed otherwise, all other chemicals were purchased from Sigma-Aldrich.
Ni-NTA resin and BL21(DE3)pLysS cells were purchased from Millipore.
Complete EDTA-Free protease inhibitor was purchased from Roche.
Protein puriﬁcation. All steps of ATP-PRT and PPase puriﬁcation were performed
at 4 ˚C using an AKTA puriﬁer 10 (GE Healthcare). Frozen BL21(DE3)pLysS
(pJ411::hisG and pJ411::ppa) 50 grams of cells were thawed on ice, resuspended in
buffer A (20 mM triethanolamine (TEA) pH 7.8, 300 mM NaCl, and 50 mM
imidazole containing lysozyme, Complete® protease inhibitor cocktail and DNase)
and lysed by sonication. After centrifugation at 25000 g for 30 min, the soluble
fraction was loaded on a 100 ml Ni-NTA column and protein eluted by a 0 to 100%
gradient of buffer B (20 mM TEA pH 7.8, 300 mM NaCl and 500 mM imidazole).
UV-Vis peak fractions were analysed by SDS-PAGE, performed on a PhastSystem
(GE Healthcare). Fractions containing only ATP-PRT or PPase were pooled, dia-
lyzed into 20 mM TEA (pH 7.8), concentrated, ﬂash-frozen and stored at −80 ˚C.
This protocol allowed the puriﬁcation to homogeneity of 1 g of ATP-PRT and 0.5 g
of PPase. ATP-PRT concentration was determined using absorbance at 280 nm
(ε280= 20,800M−1 cm−1). After the Ni-NTA column step, ATP-PRT protein for
crystallization was further puriﬁed by gel ﬁltration using a Sephadex S200 16/600
column and concentrated in the elution buffer (20 mM Tris-HCl pH 7.8, 100 mM
NaCl) to a ﬁnal concentration of 13 mg/ml before ﬂash freezing.
ATP-PRT activity measurements. Steady-state kinetic measurements were
conducted at 25 °C± 0.2 °C with a Shimadzu UV-2550 spectrophotometer
equipped with dual-beam optics and a Peltier system for temperature control.
Initial velocities for the forward reaction of ATP-PRT were measured by following
the formation of PR-ATP (ε290= 3,600 M−1 cm−1), in the presence of PPase.
Pyrophosphatase is essential for this assay, as the equilibrium constant lies
towards formation of ATP and PRPP. A typical reaction mixture contained 50 mM
Tris-HCl (pH 8.5), 7 mM MgCl2, 200 mM KCl, 3 mM ATP, 1.5 mM PRPP, 600 nM
PPase and 450 nM ATP-PRT.
L-His analogue screening. To determine the effect of 11 commercially available
analogues on L-His, ATP-PRT activity was assayed in the presence of saturating
concentrations of substrates and metals, variable concentrations of L-His and in the
presence of 1 mM of each of the analogues (with the exception of compound 1,
where a concentration of 0.9 mM was used). To determine the effect of each
analogue on enzyme activity (in the absence of L-His), ATP-PRT activity was
measured in the presence of saturating concentrations of substrates and metals, and
variable concentrations of each analogue (up to 5 mM).
Activation kinetics. To determine the steady-state activation parameters and
patterns associated with TIH, ATP-PRT activity was studied in the presence of
variable concentrations of one substrate, PRPP or ATP, ﬁxed saturating
concentrations of the co-substrate (ATP or PRPP) and metals, and several ﬁxed
concentrations of TIH.
Inhibition kinetics in the presence of activator. To determine the interaction
between L-His and TIH, ATP-PRT activity was studied in the presence of variable
concentrations of one substrate, PRPP or ATP, ﬁxed saturating concentrations of
the other substrate (ATP or PRPP) and metals, and several ﬁxed concentrations of
L-His. The experiment was repeated at several ﬁxed concentrations of TIH.
Activity rescue by TIH. ATP-PRT activity was studied in the presence of
0.4 mM L-His, a concentration 20-fold higher than L-His Ki, which fully inhibited
ATP-PRT. Increasing concentrations of TIH were then added to the reaction, up to
8 mM TIH, a concentration 4-fold higher than TIH KA.
1H NMR spectroscopy. NMR spectra were recorded at 25 °C on a Bruker
Avance-600 spectrometer equipped with a triple resonance cryo-probe and
operating at a 1H frequency of 600MHz. Saturation transfer difference (STD)
spectra43 of 20 µM ATP-PRT in the presence of ﬁxed concentration of TIH and
variable concentrations of L-His were recorded in 50 mM sodium phosphate buffer
(pH 8.0). Spectra with on-resonance pre-saturation of the enzyme at 0.8 ppm were
recorded with a saturation time of 2 s. An off-resonance control spectrum was
recorded with a saturation time of 2 s. Water suppression was achieved by
excitation sculpting44. Data processing and spectral subtractions were performed
using Bruker TopSpin 3.2 software.
Crystallization and X-ray data collection. All crystals of ATP-PRT complexes
with either L-His or TIH were obtained by co-crystallization experiments at 18 °C
using the sitting drop vapour diffusion method. Drops of 0.2 µl (protein stock:well
solution 1:1) were set-up with the assistance of the Oryx protein crystallization
robot. Protein concentration was 9.3 mg/ml whereas the ligands concentration was
100 µM and 5.5 mM for L-His and TIH, respectively. Crystals of ATP-PRT
complexes with TIH and L-His were obtained from condition 4 of Classics Lite
Suite crystallization screen by Qiagen (2.5 %(v/v) isopropanol, 1.0 M ammonium
sulphate). Crystals of ATP-PRT in complex with TIH grown in the presence of
ATP, although no positive density for ATP molecule could be located, were
obtained from condition 71 of the Protein Complex Suite by Qiagen (0.1 M Sodium
acetate anhydrous pH 5.0, 1.5 M Ammonium sulphate). Crystals were frozen
adding 20 % (v/v) glycerol to the mother liquor for cryo-protection and stored in
liquid nitrogen until data collection. Diffraction data were collected at beamline
IO4 at the Diamond Light Source, UK. Data collection temperature was 100 K.
Wavelength for both ATP-PRT/TIH and ATP/PRT/L-His datasets was 0.9282.
Integration and scaling were performed using XDS and XSCALE via xia2 expert
system for X-ray diffraction data processing45, 46. Crystals belong to the
rhombohedral space group H 3 2 with one molecule in the crystallographic
asymmetric unit, which gives a solvent content of 54–56%. Subsequent data
handling was carried out using the CCP4 software package47.
Structure determination and reﬁnement. Molecular replacement was carried out
with PHASER42, using as a search model the coordinates of M. tuberculosis ATP-
PRT complexed with L-His and AMP (PDB code 1NH8), but with the ligands and
solvent molecules removed. Models were improved and reﬁned alternating cycles
of model correction by Coot43 and restrained reﬁnement by Refmac44 and Phenix.
Reﬁne45. Figures were drawn using either Coot43 or PyMol46. For each structure,
284 amino acids of the native protein are visible in the molecule. Residues R26 to
V40 and R184 to E194 could be ﬁtted, but display higher ﬂexibility as evidenced by
less well-deﬁned electron density. The bound ligands are clearly deﬁned in both
structures and reﬁne well. A summary of the data collection and reﬁnement sta-
tistics is given in Table 3. Ramachandran statistics are 97, 3.2 and 0.0 % for most
favoured, additionally allowed and disallowed residues of ATP-PRT/TIH and 98,
1.4 and 1.1% for ATP-PRT/L-His.
Native ion-mobility mass spectrometry. On the day of analysis, the buffer
was exchanged to 100 mM ammonium acetate buffer (Fisher Scientiﬁc,
Loughborough, UK) of speciﬁed pH, using micro Bio-Spin Chromatography
columns (Micro Bio-Spin 6 Columns, Tris) following the instructions speciﬁed by
the manufacturer. The desalting procedure was performed four to ﬁve times to
achieve desired sample quality. pH of the buffer was adjusted with ammonia
supplied by VWR International Ltd (UK). Solution pH readings were taken using a
pH metre (Jenway 3305). High purity water was obtained from an Arium 611 water
puriﬁcation unit (Sartorius, Göttingen, Germany) ﬁtted with a 0.2 µm ﬁlter.
The IM-MS data were acquired on a Synapt G2S HDMS (Waters, Manchester,
UK). Samples were ionized using nano-elecrospray ionization (nESI) method,
where protein species were charged and transferred from solution into the gas
phase. nESI capillaries were prepared in-house from thin-walled borosilicate
capillaries (inner diameter 0.9 mm, outer diameter 1.2 mm, World Precision
Instruments, Stevenage, UK) using a Flaming/Brown P-97 micropipette puller
(Sutter Instrument Company, Novato, CA, USA). These were then ﬁlled with
sample using micro-loading tips (Eppendorf, Hamburg, Germany). A positive
voltage was applied to the solution via 0.125 mm platinum wire (Goodfellow
Cambridge Ltd., Huntingdon, UK) inserted into the capillary. Gentle conditions
were applied to preserve the native-like structure: capillary voltage 1.6 kV, sampling
cone 99 V, source temperature 20 °C, trap collision energy 5.6 V, and transfer
collision energy 2 V. The pressure of the backing region was 8.3 mbar. For IM-MS,
the helium cell and the IMS gas ﬂows were 180 and 90 ml min−1, respectively,
the IMS wave velocity was 617 m s−1, and the IMS wave height was 40 V.
Nitrogen was the carrier gas. Data were acquired and processed with MassLynx
software (Waters, Manchester, UK).
Steady-state data analysis. Steady-state data were ﬁtted using the nonlinear,
least-squares, curve-ﬁtting programs of Sigma-Plot for Windows, version 11.0.
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Individual saturation curves were ﬁt to Eq. 1
v ¼ VS= Sþ Kð Þ ð1Þ
where V is the maximal velocity, S is the substrate concentration, and K is the
Michaelis constant for the substrate (Km). Inhibition data obtained under
saturating concentrations of substrates and metals, and variable concentration of
L-His, were ﬁt to Eq. 2
v ¼ v0= 1þ I=IC50ð ÞnH½  ð2Þ
where v0 is the uninhibited velocity, I is the L-His concentration, IC50 is the
concentration of L-His necessary to give 50% inhibition and nH is the Hill number.
Activation data obtained under saturating concentrations of substrates and metals
and variable concentration of TIH were ﬁt to Eq. 348, 49
v ¼ v0 þ ðvamax  v0Þ ´AnH½ = ACnH50 þ AnH½ f g ð3Þ
where vamax is the maximal velocity at maximum activation, A is the concentration
of the activator TIH and AC50 is the concentration of TIH necessary to increase the
velocity by 50%. Activation data showing linear, non-essential activation pattern in
a double-reciprocal plot were ﬁt to Eq. 438, 39
v ¼ VS= K 1þ A=KAð Þ= 1þ βA=αKAð Þ½ þS 1þ A=αKAð Þ= 1þ βA=αKAð Þ½ f g ð4Þ
where KA is the activator dissociation constant, α is the constant that denotes the
modiﬁcation of the substrate and activator dissociation constants in the presence of
each other and β is the constant of the modiﬁcation of the catalytic constant.
Inhibition data showing linear, uncompetitive patterns in double-reciprocal plots
were ﬁt to Eq. 5
v ¼ VS= K þ S 1þ I=Kið Þ½  ð5Þ
where Ki is the dissociation constant for the enzyme-inhibitor complex. Inhibition
data showing linear, noncompetitive patterns in double-reciprocal plots were ﬁt to
Eq. 6
v ¼ VS= K 1þ I=Kið Þ þ S 1þ I=Kið Þ½  ð6Þ
Tertiary replots of the slopes and intercepts against activator concentration were
ﬁt to Eq. 750
Slope=Intercept ¼ y0 þ y1 A=KAð Þ½ = 1þ A=KAð Þ½  ð7Þ
where y0 is the value of slope or intercept in the absence of activator and y∞ is the
value of slope or intercept in the presence of inﬁnite concentration of activator.
Data availability. The atomic coordinates and the structure factors for
M. tuberculosis ATP-PRT in complex with L-His and TIH have been deposited into
the Protein Data Bank under the accession codes 5LHU and 5LHT. The UniProt
accession codes P9WMN1 and P9WI55 for M. tuberculosis ATP-PRT and PPiase,
respectively were used in this study. All other data are available from the
corresponding author on reasonable request.
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